Mrinalini Dey DrMiniDey
6 days 16 hours ago
What makes a good rheum learning platform?
@rheumnow’s Dr Jack Cush gives a masterclass in online learning and medical education, including the background to RheumNow.
#EULAR2026 @EMEUNET https://t.co/2cXpRXPK13
Nelly ZIADE 🍀 Nellziade
6 days 16 hours ago
What do you think about this cartoon-style format for posters?
A- I love it!
B- It’s Ok but I prefer classic
As for the content: Axia digital therapeutic app improves mobility, BASDAI, sleep an sexual function in 32 patients
#POS0199 #EULAR2026 @rheumnow https://t.co/mV83dMF4vi
Dr. John Cush RheumNow
6 days 16 hours ago
Our expanded #EULAR2026 coverage is made possible by support from Bristol Myers Squibb and UCB. All content is independently chosen and produced by the RheumNow faculty.
Nelly ZIADE 🍀 Nellziade
6 days 16 hours ago
Which imaging test has the highest carbon footprint???
Think wisely before prescribing 🩻
#EULAR2026
@RheumNow https://t.co/36Ej8smWRd
Mrinalini Dey DrMiniDey
6 days 16 hours ago
Did you take part in #RheumaVision this year?
@cristianasieiro takes us through the past, present & future of this innovative initiative, which held its final yesterday at #EULAR2026.
You can watch all the videos online- and be sure to participate next year!
@EMEUNET
@RheumNow https://t.co/liWzYYbIxI
Nelly ZIADE 🍀 Nellziade
6 days 16 hours ago
🩺🌳When good clinical practice meets reducing environmental burden of healthcare:
Rheumatologists can do a lot!
Less is more ⬇️
Thank you @eular_org for planning environmental awareness sessions
Looking forward to #greener congresses
#EULAR2026
@RheumNow https://t.co/5FwARRi92m
Mrinalini Dey DrMiniDey
6 days 16 hours ago
#RheumMadness comes to #EULAR2026!
Dr David Leverenz takes us through the background and process of this firm favourite in rheum education. An excellent example of gamification for medical education more broadly.
@RheumNow https://t.co/lmgkJbTgBm
Nelly ZIADE 🍀 Nellziade
6 days 16 hours ago
Another reason for NOT prescribing ANA (and other tests) as a “screening” test when not indicated:
High carbon footprint!
#EULAR2026
@rheumnow https://t.co/BAuzQuZ0Iv
Md Yuzaiful Md Yusof Yuz6Yusof
6 days 16 hours ago
#EULAR2026 OP0338 More evidence for treatment-to-target in #SLE. Longitudinal renal function analysis of Asia Pacific cohort: achieving LLDAS at least 50% of the time (LLDAS50) is assoc. with reduced eGFR decline independent of age, baseline eGFR, & renal involvement @RheumNow https://t.co/KduU1qtkhF
Nelly ZIADE 🍀 Nellziade
6 days 17 hours ago
Looking forward to CAR T cell therapy trials in #SSc
Phase 2 and 3 studies presented at
#HOT session by Pr Oliver Distler
#CAR_T
#EULAR2026 @RheumNow https://t.co/bmXZpF2wKg
sheila RHEUMarampa
6 days 17 hours ago
Dr. Laura Andreoli shares this slide showing the impact of rheumatic disease in reproductive health as described by Dr. MOstensen.
These interplay of factors affect patients and should be taken into consideration when managing fertility & pregnancy.
@RheumNow #EULAR2026 https://t.co/fB9kuD4kXo
Mrinalini Dey DrMiniDey
6 days 17 hours ago
Starting the “Imaging innovation in RA” session with #OP0343: Singapore investigators developed an AI-based thermography model to detect RA wrist inflammation using thermal hand images, achieving an AUC of 0.87 against ultrasound power doppler as reference. #EULAR2026 @RheumNow https://t.co/2v39E6VOWB
Jiha Lee JihaRheum
6 days 17 hours ago
Personalized #RA treatment based on Ab status and early response: better than routine care? PRIMERA RCT (n=308) says not yet. b/tsDMARD use at 10m: 21% tailored vs 17% routine. Disease activity curves identical. MTX + T2T still the standard for most. @RheumNow #EULAR2026 POS0258 https://t.co/W9FVoqTcMq
Idiopathic inflammatory myopathies (IIM) are a heterogenous group of autoimmune conditions with substantial morbidity. EULAR in collaboration with the American College of Rheumatology (ACR) introduced classification criteria for the major subgroups in 2017,1 but there is a need for contemporary real-world data to understand the burden – and well as new ways of assessing disease activity.
Dr. John Cush RheumNow
6 days 19 hours ago
RheumNow’s expanded coverage of the #EULAR2026 annual meeting is sponsored by Bristol Myers Squibb and UCB. RheumNow and its faculty independently select all coverage content.
